Payment overview · 2025
General Payments
$372.28
11 reported records · 6 companies
Healthcare provider profile · identity verified
Shameka Danielle King, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · ORANGE PARK, FL · NPI 1093478331
Verified facts
What the public records show
CMS Open Payments records show Shameka Danielle King, ARNP received $372.28 in general payments during 2025 across 11 reported records.
Amgen Inc. accounted for 31.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $115.78 | 31.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $92.97 | 25.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $88.43 | 23.8% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.98 | 8.1% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $25.32 | 6.8% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $19.80 | 5.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $372.28 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $115.78 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $92.97 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $72.09 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.98 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $25.32 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $20.28 | 1 | 2025 |
Source payment records
|
|||||
| Extended Holter Normalized: extended holter |
Device | Philips North America LLC | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 264 | 112 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 183 | 65 |
| Gabapentin | Gabapentin | 181 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 154 | 67 |
| Losartan Potassium | Losartan Potassium | 145 | 56 |
| Omeprazole | Omeprazole | 129 | 48 |
| Levothyroxine Sodium | Levothyroxine Sodium | 112 | 46 |
| Lisinopril | Lisinopril | 108 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 107 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 102 | 43 |
| Furosemide | Furosemide | 91 | 50 |
| Metformin Hcl | Metformin Hcl | 87 | 33 |
| Spironolactone | Spironolactone | 86 | 33 |
| Azithromycin | Azithromycin | 85 | 70 |
| Januvia | Sitagliptin Phosphate | 83 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 80 | 19 |
| Montelukast Sodium | Montelukast Sodium | 77 | 34 |
| Ozempic | Semaglutide | 77 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 75 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 73 | 31 |
| Trazodone Hcl | Trazodone Hcl | 72 | 32 |
| Carvedilol | Carvedilol | 71 | 30 |
| Meloxicam | Meloxicam | 70 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 70 | 32 |
| Methocarbamol | Methocarbamol | 66 | 42 |
| Quetiapine Fumarate | Quetiapine Fumarate | 65 | 20 |
| Potassium Chloride | Potassium Chloride | 63 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 60 | 31 |
| Alprazolam | Alprazolam | 59 | 16 |
| Eliquis | Apixaban | 59 | 37 |
| Jardiance | Empagliflozin | 56 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 53 | 27 |
| Prednisone | Prednisone | 52 | 35 |
| Alendronate Sodium | Alendronate Sodium | 51 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 50 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 24 |
| Farxiga | Dapagliflozin Propanediol | 48 | 14 |
| Naproxen | Naproxen | 47 | 19 |
| Mirtazapine | Mirtazapine | 46 | 22 |
| Cephalexin | Cephalexin | 45 | 35 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 44 | 19 |
| Fluconazole | Fluconazole | 43 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 23 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 27 |
| Ondansetron Odt | Ondansetron | 40 | 19 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 40 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | 12 |
| Nifedipine Er | Nifedipine | 39 | 12 |
| Sertraline Hcl | Sertraline Hcl | 39 | 18 |
| Trulicity | Dulaglutide | 39 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 38 | 17 |
| Ibuprofen | Ibuprofen | 38 | 17 |
| Simvastatin | Simvastatin | 38 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 13 |
| Buspirone Hcl | Buspirone Hcl | 36 | 14 |
| Clonazepam | Clonazepam | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 27 |
| Famotidine | Famotidine | 34 | 20 |
| Bupropion Xl | Bupropion Hcl | 33 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | suppressed |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | 14 |
| Bumetanide | Bumetanide | 32 | 16 |
| Lactulose | Lactulose | 32 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 20 |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 13 |
| Lorazepam | Lorazepam | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | 11 |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Allopurinol | Allopurinol | 28 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | 12 |
| Humalog Kwikpen U-200 | Insulin Lispro | 26 | suppressed |
| Topiramate | Topiramate | 25 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | 14 |
| Primidone | Primidone | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 23 | 14 |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | 12 |
| Methylprednisolone | Methylprednisolone | 21 | 17 |
| Nystatin | Nystatin | 21 | 13 |
| Vraylar | Cariprazine Hcl | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 13 |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 13 |
| Mupirocin | Mupirocin | 14 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Diazepam | Diazepam | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $372.28 · 11 records | Amgen Inc. | BREZTRI, EVENITY, Extended Holter, Kerendia, PROLIA, QULIPTA, REXULTI, UBRELVY, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error